Drug intelligence / Profile preview

RFUS-949

Development stage: Phase 1
Lead developer: Yichang Humanwell Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

RFUS-949 is a Class 1 new chemical entity (small molecule) developed by Yichang Renfu Pharmaceutical, a subsidiary of Wuhan Humanwell Hi-Tech Industry (Humanwell Healthcare Group). It is formulated as an oral tablet intended for the treatment of acute and chronic pain. In May 2024, the drug received clinical trial approval from China's National Medical Products Administration (NMPA) to initiate Phase 1 clinical studies. These initial trials are designed to evaluate the safety, tolerability, and pharmacokinetic characteristics of RFUS-949 in healthy Chinese subjects. At the time of its clinical entry, the developer noted that no similar products had been approved for marketing in China.

Targets

SIGMAR1 (Sigma non-opioid intracellular receptor 1)

Beyond the preview

Go deeper on RFUS-949.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RFUS-949.

Explore the full profile